ArticleNature communications2016
GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Abdominal aortic calcification and the risk of bone fractures: a meta-analysis of prospective cohort studies.Journal of bone and mineral metabolism · 2018Pooled it
- Article
- Tooth Movement Modulation and Root Protection via Piezo1-Mediated Production of Superoxide Dismutase 3.Journal of periodontal research · 2026Article
- Enhancer-mediated Etv4 activation stimulates osteogenic differentiation.Nature communications · 2026Article
- Elevated circulating GDF11 and its role in age-related sarcopenia: insights from clinical, transcriptomic, andFrontiers in aging · 2026Article
- Prolonged fasting promotes systemic inflammation and platelet activation in humans: A medically supervised, water-only fasting and refeeding study.Molecular metabolism · 2025Article
- Hypoxia-Induced O-GlcNAcylation of GATA3 Leads to Excessive Testosterone Production in Preeclamptic Placentas.MedComm · 2025Article
- Roles of myokines in osteoporosis under physiological and diabetic conditions.Frontiers in endocrinology · 2025Review
- Stephanine Protects Against Osteoporosis by Suppressing Osteoclastogenesis via Inhibition of the RANKL-RANK Interaction.Journal of cellular and molecular medicine · 2024Article
- LINE-1 RNA triggers matrix formation in bone cells via a PKR-mediated inflammatory response.The EMBO journal · 2024Article
- Myeloid-derived growth factor in diseases: structure, function and mechanisms.Molecular medicine (Cambridge, Mass.) · 2024Review
- Immunoglobulin superfamily containing leucine-rich repeat (ISLR) negatively regulates osteogenic differentiation through the BMP-Smad signaling pathway.Genes & diseases · 2024Article
- A Multifunctional Therapeutic Strategy Using P7C3 as A Countermeasure Against Bone Loss and Fragility in An Ovariectomized Rat Model of Postmenopausal Osteoporosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Myokines: metabolic regulation in obesity and type 2 diabetes.Life metabolism · 2024Review
- Aging and age-related diseases with a focus on therapeutic potentials of young blood/plasma.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Dlk2 interacts with Syap1 to activate Akt signaling pathway during osteoclast formation.Cell death & disease · 2023Article
- Study on the mechanism of NLRP3 effect on the skeleton of de-ovalized mice.Biochemistry and biophysics reports · 2023Article
- A renal YY1-KIM1-DR5 axis regulates the progression of acute kidney injury.Nature communications · 2023Article
- Myogenic differentiation of human myoblasts and Mesenchymal stromal cells under GDF11 on NPoly-ɛ-caprolactone-collagen I-Polyethylene-nanofibers.BMC molecular and cell biology · 2023Article
- Molecular Basis beyond Interrelated Bone Resorption/Regeneration in Periodontal Diseases: A Concise Review.International journal of molecular sciences · 2023Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is an age-related disease that affects millions of people. Growth differentiation factor 11 (GDF11) is a secreted member of the transforming growth factor beta (TGF-β) superfamily. Deletion of Gdf11 has been shown to result in a skeletal anterior-posterior patterning disorder. Here we show a role for GDF11 in bone remodelling. GDF11 treatment leads to bone loss in both young and aged mice. GDF11 inhibits osteoblast differentiation and also stimulates RANKL-induced osteoclastogenesis through Smad2/3 and c-Fos-dependent induction of Nfatc1. Injection of GDF11 impairs bone regeneration in mice and blocking GDF11 function prevents oestrogen-deficiency-induced bone loss and ameliorates age-related osteoporosis. Our data demonstrate that GDF11 is a previously unrecognized regulator of bone remodelling and suggest that GDF11 is a potential target for treatment of osteoporosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.